Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)

The goal of this clinical trial is to compare the PCR rate between Total Neoadjuvant Treatment ±Immunotherapy in high risk locally advanced rectal cancer. The main questions it aims to answer are: * The PCR rate between the two groups * The 3years DFS between the two groups * Chemoradiotherapy and immunotherapy toxicity * Postoperative complications Participants will receive total neoadjuvant treatment ±immunotherapy followed by surgery. Researchers will compare neoadjuvant treatment ±immunotherapy to see the PCR rate.

NCT Number	NCT06229041
Lead Sponsor	Peking University Cancer Hospital & Institute Collaborators: Beijing Nanjiao Cancer Hospital
Conditions	Rectal Cancer
Enrollment	472 participants
Start Date	2023-03-29
Primary Completion	2027-10-01 (estimated)
Study Completion	2029-10-01 (estimated)
Updated on ClinicalTrials.gov	2024-01-29